No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
CUE240719P1000
- 0.10
- +0.05+100.00%
15min DelayClose Jul 12 15:59 ET
0.10High0.05Low
0.05Open0.05Pre Close11 Volume116 Open Interest1.00Strike Price60.00Turnover71.15%IV4.26%PremiumJul 19, 2024Expiry Date0.06Intrinsic Value100Multiplier7DDays to Expiry0.04Extrinsic Value100Contract SizeAmericanOptions Type-0.7118Delta3.6483Gamma12.54Leverage Ratio-0.0022Theta-0.0001Rho-8.92Eff Leverage0.0005Vega
Intraday
- 5D
- Daily
News
JMP Securities Maintains Cue Biopharma(CUE.US) With Buy Rating, Maintains Target Price $15
JMP Securities analyst Reni Benjamin maintains $Cue Biopharma(CUE.US)$ with a buy rating, and maintains the target price at $15.According to TipRanks data, the analyst has a success rate of 33.1% and
Express News | Cue Biopharma Presents Updated Data From Phase 1 Trial of Cue-101 in Recurrent/Metastatic Hpv+ Head and Neck Cancer at the 2024 Asco Annual Meeting
Cue Biopharma to Present at Two Upcoming Investor Healthcare Conferences in June 2024
BOSTON, June 03, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ:CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate
Cue Biopharma's Promising Future: A Comprehensive Buy Rating Justification
Cue Biopharma First Quarter 2024 Earnings: Beats Expectations
Express News | Cue Biopharma Shares Are Trading Lower. The Company Reported Q1 Financial Results
Comments
$Cue Biopharma(CUE.US$
Cue Biopharma Presents Updated Data from Phase 1 Trial of CUE-101 in Recurrent/Metastatic HPV+ Head and Neck Cancer at the 2024 ASCO Annual Meeting
Cue Biopharma has presented updated data from its Phase 1 trial of CUE-101 at the 2024 ASCO Annual Meeting, revealing promising results for HPV+ head and neck cancer. The combination of CUE-101 and pembrolizumab in first-line (1L) treatment showed a 46% overall response rate (ORR) and a 96% 12-month overall survival (OS). ...
Cue Biopharma Presents Updated Data from Phase 1 Trial of CUE-101 in Recurrent/Metastatic HPV+ Head and Neck Cancer at the 2024 ASCO Annual Meeting
Cue Biopharma has presented updated data from its Phase 1 trial of CUE-101 at the 2024 ASCO Annual Meeting, revealing promising results for HPV+ head and neck cancer. The combination of CUE-101 and pembrolizumab in first-line (1L) treatment showed a 46% overall response rate (ORR) and a 96% 12-month overall survival (OS). ...
$Cue Biopharma(CUE.US$ In at 7.74
Translated
$CUE— STOCK & OPTION PLAY
NEED IT TO BREAK OVER: $15.40
key indicator for MORE uptrend $15.55
confirmation uptrend - $16.16
mini breakout - $16.37
full breakout - $17.31
SEMI PARABOLIC - $18.25
stop loss - $14.31
support - $12.98. $Cue Biopharma(CUE.US$
NEED IT TO BREAK OVER: $15.40
key indicator for MORE uptrend $15.55
confirmation uptrend - $16.16
mini breakout - $16.37
full breakout - $17.31
SEMI PARABOLIC - $18.25
stop loss - $14.31
support - $12.98. $Cue Biopharma(CUE.US$
1
2
Read more